Insider Selling: Enfusion, Inc. (NYSE:ENFN) CFO Sells 4,134 Shares of Stock

Enfusion, Inc. (NYSE:ENFN) CFO Bradley Herring sold 4,134 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $41,877.42. Following the completion of the transaction, the chief financial officer now owns 266,369 shares in the company, valued at approximately $2,698,317.97. The trade was a 1.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Bradley Herring also recently made the following trade(s):

• On Friday, December 20th, Bradley Herring sold 24,443 shares of Enfusion stock. The stock was sold at an average price of $10.61, for a total value of $259,340.23.

Enfusion Price Performance

Shares of ENFN stock opened at $9.97 on Friday. Enfusion, Inc. has a one year low of $7.52 and a one year high of $11.38. The company has a market cap of $1.28 billion, a P/E ratio of 249.31, a P/E/G ratio of 3.98 and a beta of 0.95. The firm has a 50-day moving average of $10.11 and a 200-day moving average of $9.20.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ENFN shares. Piper Sandler upped their price objective on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Stifel Nicolaus upped their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Enfusion currently has a consensus rating of “Hold” and a consensus price target of $10.25.

Hedge Funds Weigh In On Enfusion

Several hedge funds have recently modified their holdings of ENFN. TenCore Partners LP bought a new position in shares of Enfusion in the third quarter valued at approximately $3,938,000. Dimensional Fund Advisors LP grew its stake in Enfusion by 57.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock valued at $4,466,000 after purchasing an additional 191,436 shares during the period. JPMorgan Chase & Co. increased its position in shares of Enfusion by 612.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock valued at $1,974,000 after purchasing an additional 178,821 shares during the last quarter. Impax Asset Management Group plc raised its stake in shares of Enfusion by 25.4% during the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock worth $6,424,000 after purchasing an additional 136,948 shares during the period. Finally, Scalar Gauge Management LLC boosted its holdings in shares of Enfusion by 21.8% in the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after buying an additional 110,000 shares during the last quarter. Institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.